PUH-71 is under clinical development by Samus Therapeutics and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase I drugs for Myeloproliferative Disorders have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PUH-71’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PUH-71 overview

PUH-71 is under development for the treatment of  myeloproliferative neoplasms, metastatic breast cancer, primary myelofibrosis, post-polycythemia vera MF, acute myelocytic leukemia and post-essential thrombocytopenia. The therapeutic candidate is administered through intravenous and oral routes. The drug candidate acts by targeting a purine scaffold, heat shock protein 90 (HSP90). The drug candidate was also under development for the treatment of T cell acute lymphocytic leukemia, Non-Hodgkin's lymphoma, and advanced solid tumors.

For a complete picture of PUH-71’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.